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AN EXPERIMENTAL MODEL FOR HUMAN MYCOPLASMA DISEASE**
Development of animal models to explore possible relationships between
mycoplasmas and chronic progressive respiratory disease of man could
take two general courses. One approach could be study of naturally-occur-
ring chronic respiratory diseases associated with mycoplasmas in animals
and birds in order to gain insight into the nature of the host-parasite rela-
tionship that could be applied subsequently to investigation of human dis-
ease. A second approach could involve attempts to produce progressive
disease in appropriate experimental hosts using mycoplasmas isolated from
patients.
There are a number of chronic respiratory mycoplasmoses of animals
and birds: examples include infections with M. pulmonis in rats, M. hyo-
rhinis in swine, and M. gallisepticum in turkeys. Discussion of the epidemi-
ology and pathogenesis of these lesions will be provided by Drs. Fabricant
and Thomas. At present no animal mycoplasmoses are known that have
pathophysiologic features resembling chronic obstructive respiratory dis-
ease of man.
Among the eight distinct mycoplasma species indigenous to man, only
Mycoplasma pneumtoniae (Eaton's atypical pneumonia agent) has proven
pathogenicity. Two other species are potentially pathogenic, although de-
finitive proof is currently lacking. The first is M. hominis which has been
associated with respiratory disease,"'2 has caused septicemia after obstetrical
or gynecologic procedures,' and has produced exudative pharyngitis in
volunteers.' The second is the T-strain group which is distinct from other
mycoplasmas in biologic properties' and contains a multiplicity of serotypes ;
these organisms have been associated with nongonococcal urethritis, but it
is not clear whether they serve as primary or secondary invaders in this
instance.' The remaining species (M. pharyngis, M. salivarium, M. orale
types 2 and 3, and M. fermentans) have no known pathogenic significance,
and apparently comprise part of the normal microbial flora of the respira-
tory and genito-urinary tracts. Isolation of these types from a variety of
pathologic specimens, such as leukemic bone marrow, suggests that they
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can be opportunistic invaders in debilitated patients. Thus, there is no evi-
dence currently relating mycoplasmas to chronic diseases of man.
This paper will be concerned with the only proven human counterpart
of the veterinary mycoplasmoses, M. pneumoniae pneumonia. For purposes
of this conference, studies involving the Syrian hamster as an experimental
model for M. pneumoniae disease will be described to indicate applications
of the model system in defining the microbiology, pathology, and immunol-
ogy of experimental disease. In addition, certain technical nuances will be
demonstrated which could apply to the development of other animal models
for studies on human mycoplasma infections. The methods used in the work
to be summarized have been described in detail elsewhere.8-1°
MICROBIOLOGIC INVESTIGATIONS
An understanding of the temporal aspects of experimental infections is
an essential prerequisite for development of a model system. Intranasal
inoculation of hamsters with M. pneumoniae broth culture results in colon-
ization throughout the respiratory tract. In the experiment depicted in
Figure 1, over 100 animals were anesthetized with intraperitoneal secobar-
bital sodium, and each received 103 colony-forming units (CFU) of M.
pneumoniae contained in 0.1 ml. of broth culture medium. At intervals, 5-6
animals were sacrificed and serial dilutions of ground lung were cultured
for the mycoplasma. This revealed that all animals were infected by 10-14
days after inoculation; multiplication of organisms had proceeded at this
point to a level of 106 CFU/gm. of lung tissue. Half of the animals yielded
the mycoplasma from their lungs four weeks after inoculation, and com-
plete clearing of infection required 12 weeks. Other studies suggest that
colonization may persist somewhat longer in the upper respiratory passages.!
PATHOLOGIC INVESTIGATIONS
Correlation of infection and pulmonary pathologic changes requires close
sequential study of both phenomena. No gross changes are apparent at
autopsy of infected hamsters, but evidence of pneumonia may be seen micro-
scopically. The appearance of pulmonary abnormalities follows growth of
the mycoplasma in the lung by 3-4 days, as shown in Figure 1, and demon-
strates a similar chronology to that described for infection above. The basic
lesion is a peribronchial cellular infiltrate, as shown in Figure 2. Usually
these lesions are not marked; uninvolved bronchi and normal pulmonary
parenchyma may be seen in the same section. At times an endobronchial
exudate may be found, varying in degree from a slight reaction (Fig. 2)
to a more severe bronchial obstruction, as shown in Figure 3. The peribron-
chial infiltration is composed predominantly of small round cells and oc-
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FIG. 1. Correlation of the microbial, pathologic and immunologic results of inocula-
tion of the Syrian hamster with Mycoplassma pneumoniae. Adlapted from G. W.
Fernald.?°
casional plasma cells (Fig. 4), while the intraluminal exudate consists
chiefly of polymorphonuclear leukocytes. No frank tissue destruction is
evident in such material. The nature of the histopathology suggests that
the changes may be due in large part to mobilization of host defense mecha-
nisms. Further insight could be gained from localization of the organisms in
relation to the pathologic reactions, but nothing suggesting mycoplasmal
forms can be found in tissue stained with hematoxylin and eosin after
formalin fixation (Figures 2-4). Thus the problem arises of finding appro-
priate techniques for the task.
Many years ago Eaton found that the organism would replicate in the
chick embryo, and Liu visualized the site by using immunofluorescent meth-
ods.ul As shown in Figure 5, which is a section of infected chick embryo
bronchus, specific immunofluorescence was localized at the bronchial epi-
thelial border. At this time it was thought that Eaton's agent was a virus
related to the Bedsoniae which was multiplying in the cytoplasm of epithel-
ial cells. Marmion and Goodburn"2 applied an intensified Giemsa stain to
similar sections fixed in acetone, with the result depicted in Figure 6. The
area revealing specific antigen by immunofluorescence was seen to contain
numerous pink-staining minute cocci located in the bronchial mucus layer.
This breakthrough led to subsequent proof that Eaton's organism was a
mycoplasma.
Application of immunofluorescent methods to study of infected hamster
lungs revealed.clumps of specifically-stained material on the bronchial
epithelial surface which increased in amount with time, paralleling organ-
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ism multiplication.8 Companion frozen sections stained by Marmion's meth-
od revealed no mycoplasmal forms of the type seen in the chick emp)ryo
(Figure 7). Resolution of this problem required evaluation of a variety of
fixatives and stains, using serial lung sections. Figure 8, depicting a section
paired with that in Figure 7, reveals extracellular coccal forms correspond-
ing to immunofluorescent areas after fixation in Van de Grift's solution and
application of a modified Brown and Brenn staining method.8 With greater
magnification (Fig. 9) it can be seen that the coccal forms occur in clumps
in the bronchial mucus layer, providing a pattern not unlike that of Bor-
detella pertussis disease. It is conceivable that the host response in M.
pneumoniae disease is mediated, as in pertussis, by extracellular products
of the organisms, since the major pathologic changes are at sites distant
from the location of the mycoplasmas.
The nuances of histologic technique discussed above indicate the im-
portance of methodology in work with mycoplasma models. Two other
considerations that bear on successful production of experimental M. pneu-
moniae disease are the history of the inoculating organism and the choice
of anesthetic agent. As indicated in Table 1, repeated passage of M. pneu-
moniae in artificial media can reduce organism virulence for the hamster;
infection is established after inoculation, but pneumonia does not occur.8
Similarly Couch, et al.,' have indicated that serial subcultivation of the
organisms reduces pathogenicity for volunteers, with the implication that
attenuated organisms could be used as vaccines via the respiratory route.
These data also suggest that alterations in mycoplasmas resulting from
manipulations in the laboratory could impede successful development of
other animal model systems.
Table 2 summarizes the effect of two anesthetic agents on the response
of hamsters to M. pneumoniae inoculation. Animals in Group A received
intraperitoneal secobarbital, while those in Group B were given anesthetic-
grade ether by inhalation. Two weeks after inoculation all animals in Group
A were infected with the mycoplasma, yielding a geometric mean count of
TABLE 1. EFFECT OF SUBCULTIVATION ON VIRULENCE OF Mycoplasma pneumoniae
(STRAIN MAC) FOR THE HAMSTER
Result*
Inoculum history Dose Infection Pneumonia
83 egg passages 10 CFU 5/6 6/6
78 egg, 21 agar,
11 broth passages 10 CFU 5/5 0/5
* No. positive/no. studied.
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TABLE 2. EFFECT OF ANESTHETIC AGENT ON Mycoplasma pneumoniae DISEASE
IN THE HAMSTER
Result*
Group Anesthetic Infection** Pneumonia
A Secobarbital 6/6 6/6
B Ether 4/6 0/6
* No. positive/no. studied.
** Yield, log1n CFU/gm. lung: Group A, 6.2; Group B, 4.13, geometric mean.
106.2 CFU/gm. of lung tissue. Only two-thirds of the ether recipients
proved to be infected, and quantitative recovery of organisms was reduced
by 99 per cent. All animals in Group A, but none in Group B, developed
pneumonia. Thus ether has a detrimental effect on experimental disease,
which may result from destruction or alteration of the organisms contained
in the inoculum. The exquisite sensitivity of M. pneumoniae to ether is
demonstrated in vitro by the experiment depicted in Figure 10. On exposure
of broth culture to 20 per cent ether, the extrapolated half-life of the organ-
isms was found to be less than 30 seconds. This probably reflects solubility
of the sterol and phospholipid membrane components of the mycoplasma in
an organic solvent.
IMMUNOLOGIC INVESTIGATIONS
One additional application of the hamster model in studying M. pneu-
moniae disease is the development of immune responses and how these
relate to the pathogenesis of disease. Figure 1 depicts the results of tests
for complement-fixing and growth-inhibiting antibodies in hamsters inocu-
lated with virulent M. pneumoniae. The growth inhibition technique as
performed in this laboratory involves titration of organisms in 10 per cent
antiserum, so that the result is expressed as the capacity of serum to in-
hibit growth in colony-forming units. This technique has twice the sensi-
tivity of the obverse method, which is titration of serum in the presence of
a constant inoculum of organisms.'
Six months were required in the experiment depicted to follow initiation
and resolution of infection and pneumonitis, and to detect development and
decline of the immune responses measured. Both responses were first de-
tected when pneumonic changes reached their peak, between 2 and 3 weeks
post-inoculation. The complement-fixing activity attained its highest level
around six weeks, at which point 20 per cent of the animals still had pneu-
monia. Growth inhibiting ability of serum peaked at about 10 weeks, and
provides a better correlation with the disappearance of both organisms and
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pneumonia. This dissociation of immune responses is less marked than is
the case in man: complement fixation is maximal at a corresponding point,
but growth inhibition rises much more slowly and reaches its highest level
5 or 6 months after onset of symptoms. In man it has been shown that the
divergence of these biological responses depends upon the sequential ap-
pearance of the immunoglobulin classes, IgM predominating early and IgG
later, and upon the degree to which each immunoglobulin participates in
the various serologic reactions employed.' The hamster produces little IgM
in response to M. pneumoniae infection, and the serologic activity illustrated
in Figure 1 is mediated principally by IgG.10
While these responses are useful for diagnostic purposes, they appear
to reflect protective immunity only secondarily. Hamsters immunized with
killed organisms develop serologic responses identical to those of infected
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moniae. In contrast, infected animals resist re-infection if challenged after
the twelfth week.'0 The bronchial secretions of hamsters contain both IgG
and IgA, as is the case in man. As has been demonstrated earlier, M.
pneumoniae infection is superficial in nature, and it is likely that local cel-
lular or secretory immunity plays a major role in resistance to disease.
CONCLUSION
This discussion of an animal model for M. pneumoniae disease has sev-
eral implications and applications concerning possible relationships between
mycoplasmas and chronic obstructive pulmonary disease in man. At present
only M. pneumoniae is recognized among the several species indigenous to
man as having definite respiratory pathogenicity. While the clinical mani-
festations of M. pneumoniae disease are acute, and there are as yet no known
chronic sequelae, the microbial, epidemiologic, and immunologic aspects
follow a more subacute pattern. As with commensal bacteria, commensal
mycoplasma species may be recovered from sputa of patients with chronic
bronchitis.1" The pathogenic significance of these organisms has not been
assessed; a logical first step could be studies of the type that have been
described using animal models. While data from such experiments are not
directly transferable to man, they may provide insight into basic and essen-
tially unexplored pathogenetic mechanisms which can direct appropriate
design and interpretation of studies in the human host.
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